| 摘要 |
Disclosed herein is the use of compounds of formula I, in particular N-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-N’-(4-fluorophenyl)cydopropane-1,1-dicarboxamide (carboaztinib/XL184) for treating bone disorders such as osteoporosis. |
